AI triggers an innovation-driven growth phase in the biotech sector. Two leading stocks are moving onto the watchlist for the US model portfolio!

We have successfully invested in AI infrastructure stocks. Now, we see biotechnology as a future beneficiary of AI. There will be innovation-driven growth. Here are the key points in favor of this: AI finds the right target area. Every medication needs a point of attack in the body where it stops the disease. Finding this point required decades of experience plus luck. Algorithms today search through millions of biological datasets, uncovering targets that no one had previously considered. AI replaces trial and error with calculations. In the...